A pT1c fallopian tube carcinosarcoma: a case report

Carcinosarcomas of the fallopian tube are extremely rare tumors with poor prognosis. They are more frequent in women in the fifth or sixth decade and often revealed by abdominal pain or gynecological bleeding. The author reports the rare case of a 73-year-old women presenting with post menopausal gynecological intermittent bleeding for two months. Ultrasonography and MRI showed a four-cm heterogeneous right annexial mass. Right annexectomy by laparoscopy showed a malignant tumor. The patient unde went total hysterectomy, a bilateral salpingo-oophorectomy, appendectomy, omentectomy, and pelvic and lombo-aortic lymph node dissections. Pathologic diagnosis revealed a non-heterologous carcinosarcoma arising from the right fallopian tube: pT1c N0, FIGO Stage IC. Six cycles of adjuvant chemotherapy paclitaxel+carboplatin were decided. Computed tomography scan after three cycles did not show any sign of recurrence. The patient is following chemotherapy. Because fallopian tube carcinomas are a very rare disease, no standard therapy exists. Data from many institutions may improve knowledge and management.

Fallopian tube carcinosarcoma; Chemotherapy; Platinium-based chemotherapy; Rare tumor; Gynecological bleeding.

[1] Henderson S.R., Harper R.C., Salazar O.M., Rudolph J.H.: “Primary carcinoma of the fallopian tube: difficulties of the diagnosis and treatment”. Gynecol. Oncol., 1977, 5, 168.

[2] Hanjani P., Peterson R.O., Bonnell S.A.: “Malignant mixed Müllerian tumor of the fallopian tube: report of a case and review of literature”. Gynecol. Oncol., 1980, 9, 381.

[3] Imachi M., Tsukamoto N., Shigematsu T., Watanabe T., Uehira K., Amada S., Umezu T., Nakano H.: “Malignant mixed Müllerian tumor of the fallopian tube: report of two cases and review of literature”. Gynecol. Oncol., 1992, 47, 114.

[4] Riska A., Leminen A., Pukkala E.: “Sociodemographic determinants of incidence of primary fallopian tube carcinoma, Finland 1953-97”. Int. J. Cancer, 2003, 104, 643.

[5] Inal MA., Hanhan M., Pilanci B., Tinar S.: “Fallopian tube malignancies: experience of Social Security Agency Aegean Maternity Hospital”. Int. J. Gynecol. Cancer, 2004, 14, 595.

[6] Stewart S.L., Wike J.M., Foster S.L., Michaud F.: “The incidence of primary fallopian tube cancer in the United States”. Gynecol. Oncol., 2007, 107, 392.

[7] Ajithkumar T.V., Minimole A.L., John M.M., Ashokkumar O.S.: “Primary fallopian tube carcinoma”. Obstet. Gynecol. Surv., 2005, 60, 247.

[8] Puls L.E., Davey D.D., DePriest P.D., Gallion H.H., van Nagell J.R. Jr., Hunter J.E., Pavlik E.J.: “Immunohistochemical staining for CA- 125 in fallopian tube carcinosarcomas”. Gynecol. Oncol., 1993, 48, 360.

[9] Gollard R., Kosty M., Bordin G., Wax A., Lacey C.: “Two unusual presentations of mullerian adenosarcoma: case report, literature review, and treatment considerations”. Gynecol. Oncol., 1995, 59, 412.

[10] Sutton G., Brunetto V.L., Kilgore L., Soper J.T., McGehee R., Olt G., et al.: “A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus : a Gynecologic Oncology Group Study”. Gynecol. Oncol., 2000, 79, 147.

[11] Curtin J.P., Blessing J.A., Soper J.L., DeGeest K.: “Paclitaxel in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group Study”. Gynecol. Oncol., 2001, 83, 268.

[12] Menczer J., Levy T., Piura B., Chetrit A., Altaras M., Meirovitz M., et al.: “A comparison between different postoperative treatment modalities of uterine carcinosarcoma”. Gynecol. Oncol., 2005, 97, 166.